Pitolisant

DB11642ApprovedInvestigationalSmall moleculeHistamine-3 Receptor Antagonist/Inverse Agonist

Pitolisant is an antagonist and inverse agonist at the histamine H3 receptor that is used to treat narcolepsy in adults. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations.

Chemical structure of Pitolisant
Mechanism
Curator reviewed · 13 references
Primary indication
Pitolisant is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in patients six years of age and older with narcolepsy.Curator reviewed · 4 structured indications
Formula / weight
C17H26ClNO · 295.85 g/mol (avg)
First approval
Canada, 2026 · United States, 2019 · European Union, 2016
Code names
BF-2.649
Brand names
  • Ozawade
  • Wakix

Resolves to

Structure
InChIKeyNNACHAUCXXVJSP-UHFFFAOYSA-NSMILESClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
Transporters

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
1,804Drug interactionsStructured to mechanism, not free text
Sign in
33Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
4ContraindicationsEach with its own population and attribute set
Sign in
20Marketed productsAcross 4 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 28 drug categories
Sign in
32+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Pitolisant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account